Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axim Biotechnologies Inc
(OP:
AXIM
)
0.0032
+0.0002 (+6.67%)
Streaming Delayed Price
Updated: 3:37 PM EST, Nov 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
221,450
Open
0.0030
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0030
Today's Range
0.0030 - 0.0035
52wk Range
0.0020 - 0.0220
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AXIM Biotechnologies Receives Medical Device Manufacturing License
May 29, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
March 27, 2024
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s
Via
TheNewswire.com
Performance
YTD
-84.31%
-84.31%
1 Month
-20.00%
-20.00%
3 Month
-67.68%
-67.68%
6 Month
-73.33%
-73.33%
1 Year
-81.40%
-81.40%
More News
Read More
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
March 27, 2024
Via
NewMediaWire
AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
February 20, 2024
Via
NewMediaWire
AXIM Biotechnologies Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
February 20, 2024
Via
TheNewswire.com
AXIM Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
December 20, 2023
Via
NewMediaWire
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease
September 12, 2023
From
AXIM Biotechnologies, Inc.
Via
Business Wire
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
August 01, 2023
From
AXIM Biotechnologies, Inc.
Via
Business Wire
Update: AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
July 12, 2023
Via
NewMediaWire
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
July 12, 2023
Via
NewMediaWire
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
May 24, 2023
Via
NewMediaWire
AXIM Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
May 23, 2023
Via
NewMediaWire
Exposures
Product Safety
AXIM Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays
April 11, 2023
Via
NewMediaWire
AXIM Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing
March 14, 2023
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
Medical Marijuana, Inc. Appoints New CEO; Highlights Renewed Focus on Profitability, Further Expansion
March 14, 2023
Via
NewMediaWire
Topics
Cannabis
Exposures
Cannabis
AXIM Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance
January 17, 2023
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent
December 13, 2022
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic Solutions
December 06, 2022
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch
October 04, 2022
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 2022
September 29, 2022
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season
July 26, 2022
From
AXIM BIOTECHNOLOGIES, INC
Via
GlobeNewswire
Will This Dry Eye Rapid Test Prove To Be A Rapid Success?
July 07, 2022
Via
Benzinga
Medical Marijuana, Inc. Reports Revenue Of $7.8M For Q1 2022
May 19, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
